OverviewSuggest Edit

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna, is used for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis, Translarna for mucopolysaccharidosis type I caused by nonsense mutation, Translarna for nonsense mutation aniridia, and Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy in collaboration with Spinal Muscular Atrophy Foundation.
TypePublic
Founded1998
HQSouth Plainfield, US
Websiteptcbio.com
Employee Ratings3.2
Culture scoreA

Latest Updates

Employees (est.) (Dec 2019)754(+48%)
Job Openings30
Revenue (FY, 2019)$307 M(+16%)
Share Price (May 2020)$49.9

Key People/Management at PTC Therapeutics

Stuart Peltz

Stuart Peltz

CEO
Neil Almstead

Neil Almstead

Executive Vice President, Research, Pharmaceutical Operations & Technology
Mark Boulding

Mark Boulding

Executive Vice President and Chief Legal Officer
Mary Harmon

Mary Harmon

Senior Vice President, Corporate Relations
VMD Mark J. Pykett

VMD Mark J. Pykett

Chief Innovation Officer
Martin Rexroad

Martin Rexroad

Senior Vice President, Human Resources
Show more

PTC Therapeutics Office Locations

PTC Therapeutics has an office in South Plainfield
South Plainfield, US (HQ)
100 Corporate Ct
Show all (1)

PTC Therapeutics Financials and Metrics

PTC Therapeutics Revenue

PTC Therapeutics's revenue was reported to be $306.98 m in FY, 2019
USD

Revenue (Q1, 2020)

68.3m

Net income (Q1, 2020)

(112.7m)

EBIT (Q1, 2020)

(93.0m)

Market capitalization (28-May-2020)

3.3b

Closing stock price (28-May-2020)

49.9

Cash (31-Mar-2020)

123.3m

EV

3.5b
PTC Therapeutics's current market capitalization is $3.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

34.7m25.2m36.8m82.7m194.4m264.7m307.0m

Revenue growth, %

(27%)46%125%

Cost of goods sold

4.6m12.7m12.1m

Gross profit

189.8m252.1m294.8m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

6.9m16.3m9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m85.5m71.4m68.3m

Cost of goods sold

39.0k758.0k1.6m3.0m2.6m3.3m2.4m3.2m3.0m

Gross profit

26.5m47.2m40.3m53.0m66.2m50.3m51.2m82.3m68.4m

Gross profit Margin, %

100%98%96%95%96%94%96%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.4m49.7m58.0m58.3m111.8m169.5m288.0m

Accounts Receivable

4.4m11.1m24.9m40.4m67.9m55.5m

Prepaid Expenses

1.6m3.9m5.9m6.7m9.2m17.9m

Inventories

4.7m10.8m16.1m19.3m
Quarterly
USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

154.1m24.0m115.9m21.2m52.9m36.8m29.2m140.7m40.2m35.7m50.3m54.1m133.0m141.8m97.7m223.8m206.9m201.1m136.1m523.6m123.3m

Accounts Receivable

1.3m3.2m5.1m8.0m22.6m19.8m27.4m32.2m33.8m38.7m45.6m59.4m42.2m46.4m77.1m60.4m52.6m

Prepaid Expenses

1.6m2.1m2.0m2.6m2.8m6.1m4.2m4.6m5.1m4.8m4.9m4.6m5.2m5.4m5.8m6.3m8.0m9.3m17.4m20.7m24.3m

Inventories

1.4m6.9m7.8m12.4m13.9m13.7m16.2m16.9m17.1m19.1m
USDY, 2020

EV/EBIT

-37.3 x

EV/CFO

-42.5 x

Financial Leverage

2.9 x
Show all financial metrics

PTC Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Agilis BiotherapeuticsJuly 20, 2018$200 m

PTC Therapeutics Online and Social Media Presence

Embed Graph

PTC Therapeutics Company Culture

  • Overall Culture

    A

    87/100

  • CEO Rating

    B

    75/100

  • Compensation

    A+

    100/100

Learn more on Comparably

PTC Therapeutics News and Updates

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of spinal muscular...

PTC Therapeutics Announces Proposed Private Offering of Convertible Senior Notes

SOUTH PLAINFIELD, N.J., Sept. 17, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing an offering of $250.0 million aggregate principal amount of its convertible senior notes due 2026 (the "Notes"), subject to market conditions and other...

PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients ...

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J., March 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 39th Annual Health Care Conference Monday, March 11th at 11:20 a.m. ET Barclays Global...

PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares

SOUTH PLAINFIELD, N.J., Feb. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the sole underwriter of its previously announced public offering of 6,720,000 shares of its common stock, which closed on January 25, 2019, has partially exercised its option...

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results

SOUTH PLAINFIELD, N.J., Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial results and provide an update on the company's business and outlook on Monday,...
Show more

PTC Therapeutics Blogs

PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)

PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA) Content Import Tue, 04/07/2020 - 16:05 PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA) Apr 7, 2020 This release is a backfill from a News Wire …

PTC Therapeutics Announces Management Change

SOUTH PLAINFIELD, N.J. , March 16, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza , Chief Operating Officer, has resigned and will be leaving the company by April 25 th , 2020. "We are grateful to Marcio for the significant contributions he has made to

PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

SOUTH PLAINFIELD, N.J. , March 2, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019 . "2019 was a year of outstanding execution for PTC.

PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy

PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy Content Import Tue, 02/18/2020 - 08:02 PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy …

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results

SOUTH PLAINFIELD, N.J. , Feb. 17, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and outlook on

PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference

PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference Content Import Mon, 02/03/2020 - 08:05 PTC Therapeutics to Host A Conference Call to Review Part 2 of the SUNFISH Clinical Trial Data at the SMA Europe Conference …
Show more

PTC Therapeutics Frequently Asked Questions

  • When was PTC Therapeutics founded?

    PTC Therapeutics was founded in 1998.

  • Who are PTC Therapeutics key executives?

    PTC Therapeutics's key executives are Stuart Peltz, Neil Almstead and Mark Boulding.

  • How many employees does PTC Therapeutics have?

    PTC Therapeutics has 754 employees.

  • What is PTC Therapeutics revenue?

    Latest PTC Therapeutics annual revenue is $307 m.

  • What is PTC Therapeutics revenue per employee?

    Latest PTC Therapeutics revenue per employee is $407.1 k.

  • Who are PTC Therapeutics competitors?

    Competitors of PTC Therapeutics include Biogen, AbbVie and Otonomy.

  • Where is PTC Therapeutics headquarters?

    PTC Therapeutics headquarters is located at 100 Corporate Ct, South Plainfield.

  • Where are PTC Therapeutics offices?

    PTC Therapeutics has an office in South Plainfield.

  • How many offices does PTC Therapeutics have?

    PTC Therapeutics has 1 office.